Elite Pharma launches generic Requip XL ropinirole extended-release tablets in US

Reuters2026/08/04 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elite Pharmaceuticals launched a generic version of Requip XL, expanding its controlled-release portfolio with a newly commercialized product.
Targets a market with USD 10 million in US sales over the 12 months ended June 2026, supporting incremental revenue potential.
Launch strengthens Elite’s competitive position in niche generics through in-house manufacturing and nationwide distribution under its Elite Laboratories label.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608040700NEWSFILECNPR____20260804_307809_1) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elite Pharma launches generic Requip XL ropinirole extended-release tablets in US

You may also like

Crypto prices